麦科格rab 对两性霉素 B MIC 的非特异性作用。
Nonspecific effect of Mycograb on amphotericin B MIC.
机构信息
Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
出版信息
Antimicrob Agents Chemother. 2012 Jul;56(7):3963-4. doi: 10.1128/AAC.00435-12. Epub 2012 Apr 16.
Abstract
Mycograb C28Y is a recombinant human antibody fragment thought to target HSP-90 and potentiate amphotericin B (AMB). Absence of in vivo efficacy led us to reevaluate its in vitro activity. Interactions between AMB and Mycograb were investigated using a checkerboard design. Addition of Mycograb or various unrelated proteins, including human serum, resulted in similar decreases in the MIC of AMB. Potentiation of AMB by Mycograb appears to be a nonspecific protein effect.
摘要
Mycograb C28Y 是一种重组人抗体片段，据认为其可靶向 HSP-90 并增强两性霉素 B（AMB）的活性。体内疗效的缺失促使我们重新评估其体外活性。采用棋盘设计研究了 AMB 与 Mycograb 之间的相互作用。添加 Mycograb 或各种不相关的蛋白质，包括人血清，均可使 AMB 的 MIC 相似降低。Mycograb 增强 AMB 的作用似乎是一种非特异性蛋白效应。
相似文献
1
Nonspecific effect of Mycograb on amphotericin B MIC.
Antimicrob Agents Chemother. 2012 Jul;56(7):3963-4. doi: 10.1128/AAC.00435-12. Epub 2012 Apr 16.
2
Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.
Diagn Microbiol Infect Dis. 2005 Jan;51(1):19-29. doi: 10.1016/j.diagmicrobio.2004.08.013.
3
Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.
Antimicrob Agents Chemother. 2011 Jul;55(7):3295-304. doi: 10.1128/AAC.01324-10. Epub 2011 Apr 18.
4
Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion.
Antimicrob Agents Chemother. 2011 Jul;55(7):3591-3. doi: 10.1128/AAC.01701-10. Epub 2011 Apr 25.
5
In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms.
Int J Antimicrob Agents. 2009 Oct;34(4):326-32. doi: 10.1016/j.ijantimicag.2009.04.011. Epub 2009 Jun 9.
6
Generation of mutants in Candida albicans with reduced susceptibility to caspofungin: influence on other antifungal products.
J Chemother. 2010 Aug;22(4):283-4. doi: 10.1179/joc.2010.22.4.283.
7
Antifungal combinations against Candida albicans biofilms in vitro.
Antimicrob Agents Chemother. 2003 Nov;47(11):3657-9. doi: 10.1128/AAC.47.11.3657-3659.2003.
8
In vitro activity of antifungal combinations against Candida albicans biofilms.
J Antimicrob Chemother. 2010 Feb;65(2):271-4. doi: 10.1093/jac/dkp429. Epub 2009 Dec 8.
9
[Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Mikrobiyol Bul. 2008 Jan;42(1):149-55.
10
Antifungal activity of amphotericin B, caspofungin and posaconazole on Candida albicans biofilms in intermediate and mature development phases.
Mycoses. 2010 May;53(3):208-14. doi: 10.1111/j.1439-0507.2009.01690.x. Epub 2009 Feb 26.
引用本文的文献
1
Harnessing the Immune Response to Fungal Pathogens for Vaccine Development.
Annu Rev Microbiol. 2022 Sep 8;76:703-726. doi: 10.1146/annurev-micro-041020-111511. Epub 2022 Jun 27.
2
The role of stress response pathways in antifungal tolerance and resistance.
iScience. 2022 Feb 19;25(3):103953. doi: 10.1016/j.isci.2022.103953. eCollection 2022 Mar 18.
3
The Role of B-Cells and Antibodies against Vaccine Antigens in Invasive Candidiasis.
Vaccines (Basel). 2021 Oct 10;9(10):1159. doi: 10.3390/vaccines9101159.
4
Biological and Physico-Chemical Characteristics of Arginine-Rich Peptide Gemini Surfactants with Lysine and Cystine Spacers.
Int J Mol Sci. 2021 Mar 24;22(7):3299. doi: 10.3390/ijms22073299.
5
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.
Front Immunol. 2020 Sep 17;11:2177. doi: 10.3389/fimmu.2020.02177. eCollection 2020.
6
Targeting Crf Transglycosylases With Neutralizing Antibody Is Relevant but Not Sufficient to Erase Fungal Burden in a Neutropenic Rat Model.
Front Microbiol. 2019 Mar 26;10:600. doi: 10.3389/fmicb.2019.00600. eCollection 2019.
7
Immunomodulation as Therapy for Fungal Infection: Are We Closer?
Front Microbiol. 2018 Jul 25;9:1612. doi: 10.3389/fmicb.2018.01612. eCollection 2018.
8
The Elusive Anti- Vaccine: Lessons From the Past and Opportunities for the Future.
Front Immunol. 2018 Apr 27;9:897. doi: 10.3389/fimmu.2018.00897. eCollection 2018.
9
Heat Shock Proteins and Hsps-Associated Signaling Pathways as Potential Antifungal Targets.
Front Cell Infect Microbiol. 2017 Dec 19;7:520. doi: 10.3389/fcimb.2017.00520. eCollection 2017.
10
Antimicrobial Activity and Resistance: Influencing Factors.
Front Pharmacol. 2017 Jun 13;8:364. doi: 10.3389/fphar.2017.00364. eCollection 2017.
本文引用的文献
1
Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.
Antimicrob Agents Chemother. 2011 Jul;55(7):3295-304. doi: 10.1128/AAC.01324-10. Epub 2011 Apr 18.
2
Monoclonal antibody-based therapies for microbial diseases.
Vaccine. 2009 Dec 30;27 Suppl 6:G38-46. doi: 10.1016/j.vaccine.2009.09.105.
3
A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.
Clin Infect Dis. 2006 May 15;42(10):1404-13. doi: 10.1086/503428. Epub 2006 Apr 12.
4
Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.
Diagn Microbiol Infect Dis. 2005 Jan;51(1):19-29. doi: 10.1016/j.diagmicrobio.2004.08.013.
5
Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.
Antimicrob Agents Chemother. 2003 Jul;47(7):2208-16. doi: 10.1128/AAC.47.7.2208-2216.2003.
6
Influence of human serum on antifungal pharmacodynamics with Candida albicans.
Antimicrob Agents Chemother. 2001 Jul;45(7):2018-22. doi: 10.1128/AAC.45.7.2018-2022.2001.
7
Effect of iron on fluconazole activity against Candida albicans in presence of human serum or monocyte-derived macrophages.
Mycopathologia. 1997;138(1):29-35. doi: 10.1023/a:1006889108673.
8
Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.
Antimicrob Agents Chemother. 1991 Nov;35(11):2275-81. doi: 10.1128/AAC.35.11.2275.
Zotero 插件